Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10447953rdf:typepubmed:Citationlld:pubmed
pubmed-article:10447953lifeskim:mentionsumls-concept:C0033262lld:lifeskim
pubmed-article:10447953lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:10447953lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:10447953lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:10447953lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:10447953lifeskim:mentionsumls-concept:C0449445lld:lifeskim
pubmed-article:10447953lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:10447953lifeskim:mentionsumls-concept:C0439611lld:lifeskim
pubmed-article:10447953lifeskim:mentionsumls-concept:C0597565lld:lifeskim
pubmed-article:10447953pubmed:issue16lld:pubmed
pubmed-article:10447953pubmed:dateCreated1999-9-2lld:pubmed
pubmed-article:10447953pubmed:abstractTextThe synthesis and preliminary evaluation of a novel prodrug approach for improving the water solubility of drugs containing a tertiary amine group are reported. The prodrug synthesis involves a nucleophilic substitution reaction between the parent tertiary amine and a novel derivatizing reagent, di-tert-butyl chloromethyl phosphate, resulting in formation of the quaternary salt. The tertiary butyl groups are easily removed under acidic conditions with trifluoroacetic acid giving the N-phosphonooxymethyl prodrug in the free phosphoric acid form, which can subsequently be converted to the desired salt form. The synthesis was successfully applied to a model compound (quinuclidine) and to three tertiary amine-containing drugs (cinnarizine, loxapine, and amiodarone). The prodrugs were designed to undergo a two-step bioreversion process. The first step was an enzyme-catalyzed rate-determining dephosphorylation followed by spontaneous chemical breakdown of the N-hydroxymethyl intermediate to give the parent drug. Selected prodrugs were shown to be substrates for alkaline phosphatase in vitro. A preliminary in vivo study confirmed the ability of the cinnarizine prodrug to be rapidly and completely converted to cinnarizine in a beagle dog following iv administration.lld:pubmed
pubmed-article:10447953pubmed:languageenglld:pubmed
pubmed-article:10447953pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10447953pubmed:citationSubsetIMlld:pubmed
pubmed-article:10447953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10447953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10447953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10447953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10447953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10447953pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10447953pubmed:statusMEDLINElld:pubmed
pubmed-article:10447953pubmed:monthAuglld:pubmed
pubmed-article:10447953pubmed:issn0022-2623lld:pubmed
pubmed-article:10447953pubmed:authorpubmed-author:StellaV JVJlld:pubmed
pubmed-article:10447953pubmed:authorpubmed-author:ZygmuntJJlld:pubmed
pubmed-article:10447953pubmed:authorpubmed-author:GeorgG IGIlld:pubmed
pubmed-article:10447953pubmed:authorpubmed-author:KriseJ PJPlld:pubmed
pubmed-article:10447953pubmed:issnTypePrintlld:pubmed
pubmed-article:10447953pubmed:day12lld:pubmed
pubmed-article:10447953pubmed:volume42lld:pubmed
pubmed-article:10447953pubmed:ownerNLMlld:pubmed
pubmed-article:10447953pubmed:authorsCompleteYlld:pubmed
pubmed-article:10447953pubmed:pagination3094-100lld:pubmed
pubmed-article:10447953pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:meshHeadingpubmed-meshheading:10447953...lld:pubmed
pubmed-article:10447953pubmed:year1999lld:pubmed
pubmed-article:10447953pubmed:articleTitleNovel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs.lld:pubmed
pubmed-article:10447953pubmed:affiliationDepartment of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047, USA.lld:pubmed
pubmed-article:10447953pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10447953pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:10447953lld:chembl